Foghorn Therapeutics Inc.FHTXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -55.33% | -50.49% | +17.86% | +9.71% | +4.42% |
| Gross Profit Growth | +0.00% | -41.92% | +17.86% | -3.35% | -251.75% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +48.96% | +48.06% | +48.13% | +22.10% | +0.68% |
| Weighted Average Shares Diluted Growth | +48.96% | +48.06% | +48.13% | +22.10% | +0.68% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -1.61% | -0.68% | +1.45% | -31.15% | -33.53% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -17.02% | -17.62% | -18.91% | -42.08% | -42.34% |
| R&D Expense Growth | -5.95% | -12.18% | -15.31% | -12.21% | -18.98% |
| SG&A Expenses Growth | -16.09% | -9.53% | -6.11% | -6.32% | -4.58% |